# Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

> **NCT00245050** · PHASE3 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer
- Drug/Agent Toxicity by Tissue/Organ
- Endometrial Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** pyridoxine hydrochloride
- **DRUG:** Placebo
- **DRUG:** doxorubicin HCL liposome

## Key facts

- **NCT ID:** NCT00245050
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2008-04
- **Final completion:** 2011-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2011-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245050, "Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00245050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*